Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Goldenwell Biotech (GWLL) Shares Outstanding (Weighted Average) (2019 - 2025)

Goldenwell Biotech (GWLL) has disclosed Shares Outstanding (Weighted Average) for 6 consecutive years, with $96.4 million as the latest value for Q3 2024.

  • For the quarter ending Q3 2024, Shares Outstanding (Weighted Average) changed 0.0% year-over-year to $96.4 million, compared with a TTM value of $96.4 million through Sep 2024, changed 0.0%, and an annual FY2023 reading of $96.4 million, changed 0.0% over the prior year.
  • Shares Outstanding (Weighted Average) was $96.4 million for Q3 2024 at Goldenwell Biotech, roughly flat from $96.4 million in the prior quarter.
  • Across five years, Shares Outstanding (Weighted Average) topped out at $96.4 million in Q4 2022 and bottomed at $80.0 million in Q1 2020.
  • Average Shares Outstanding (Weighted Average) over 5 years is $90.5 million, with a median of $91.3 million recorded in 2021.
  • Peak annual rise in Shares Outstanding (Weighted Average) hit 14.15% in 2021, while the deepest fall reached 0.0% in 2021.
  • Year by year, Shares Outstanding (Weighted Average) stood at $80.0 million in 2020, then grew by 14.15% to $91.3 million in 2021, then grew by 5.6% to $96.4 million in 2022, then changed by 0.0% to $96.4 million in 2023, then changed by 0.0% to $96.4 million in 2024.
  • Business Quant data shows Shares Outstanding (Weighted Average) for GWLL at $96.4 million in Q3 2024, $96.4 million in Q2 2024, and $96.4 million in Q1 2024.